Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( SURPASS programme)
Authors' conclusion
This post hoc analysis showed that once-weekly tirzepatide had a similar safety and efficacy profile across BMI and age subgroups in East Asian participants.
Study context
- Population
- East Asian participants (94% from Japan) with T2D, baseline HbA1c 7.0%–11.0% and body mass index (BMI) ≥23 or ≥25 kg/m², treated with tirzepatide 5, 10 or 15 mg in SURPASS-1, −3, −4, −5, J-mono and J-combo; at baseline 73% had BMI ≥25 kg/m² and 74% were <65 years
- Comparison
- Tirzepatide across age and BMI subgroups
Methodological detailssubgroup analysis by age and BMI
- Subgroup analysis by age and BMI
Primary result
As reported in the abstract
HbA1c, waist circumference and BMI across age and BMI subgroups · week 52
Mean absolute HbA1c reductions across the three doses, all BMI and age subgroups
2.3% to 3.0%
Mean waist circumference reductions, all BMI and age subgroups
4.3 to 9.8 cm
Further findings
Insulin sensitivity (HOMA-IR)
- Improvements in absolute insulin sensitivity were greater with baseline BMI ≥25 kg/m²
Lipid profiles
- Improvements in lipid profiles were similar across subgroups
Safety
- Safety profile broadly similar across BMI and age subgroups
- Drug discontinuation because of AEs was higher with baseline age ≥65 years
Original publication
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( SURPASS programme). Diabetes Obes Metab. Published 20 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →